Treatment of Class IV Lupus Nephritis with Mycophenolate Mofetil Monotherapy

Lupus nephritis (LN) occurs in up to 60% of systemic lupus erythematosus patients. Combination therapy involving a corticosteroid and cyclophosphamide or mycophenolate mofetil (MMF) has been a standard therapy for LN. However, clinicians generally prefer to minimize steroid use in LN treatment. We h...

Descripción completa

Detalles Bibliográficos
Autores principales: Nawata, Takashi, Kubo, Makoto, Fujii, Shohei, Shiragami, Kosaku, Ikegami, Tadayoshi, Kobayashi, Shigeki, Hisano, Satoshi, Yano, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096032/
https://www.ncbi.nlm.nih.gov/pubmed/29491296
http://dx.doi.org/10.2169/internalmedicine.0304-17
Descripción
Sumario:Lupus nephritis (LN) occurs in up to 60% of systemic lupus erythematosus patients. Combination therapy involving a corticosteroid and cyclophosphamide or mycophenolate mofetil (MMF) has been a standard therapy for LN. However, clinicians generally prefer to minimize steroid use in LN treatment. We herein report the case of a Japanese man with LN whose severe chronic heart failure prevented us from using steroid therapy. Instead, his LN was successfully treated with MMF monotherapy. Based on our experience with this case, we suggest that MMF monotherapy may represent a feasible LN treatment option in patients who cannot tolerate steroid therapy.

Ejemplares similares